Exelixis Inc (EXEL) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Total Assets Chart for Exelixis Inc

Exelixis Inc (EXEL) total assets for FY2025 were USD 2.8B, a -3.5% change from FY2024. Exelixis Inc's total assets grew from USD 9.0M in 1998 to USD 2.8B in 2025 (31571.6% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 5.9%, 10-year CAGR of 23.9%, 20-year CAGR of 11.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$14.45B
Implied Share Price
$58.33
Enterprise Value
$13.38B
Revenue (TTM)
$2.44B
EBITDA
$1.02B
Profit Margin
35.33%
Trailing P/E
18.58
Forward P/E
13.55
Price/Book (MRQ)
7.82
Price/Sales (TTM)
5.93
EV/EBITDA
13.11
EV/Revenue
5.49
Dividend Yield
—
Book Value
$7.41
Free Cash Flow (FY2025)
$844.34M
Free Cash Flow Yield
5.84%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.